# A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

> **NCT03283696** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 24 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab
- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT03283696
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-18
- **Primary completion:** 2019-04-29
- **Final completion:** 2019-08-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283696, "A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03283696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*